



7 Clarke Drive
Cranbury, New Jersey 08520
Telephone: (609) 409-6080
Direct Facsimile: (413) 254-9245
Main Facsimile: (609) 409-6126

FAX COVER SHEET

To: Dr. Janet Epps

Company: US PTO -GAU 1635

Fax No: 703-305-7939

FROM: Viviana Amzel DATE: 4/25/01 TIME: 9:36 AM
Direct Dial: (409) 609-3035 E-Mail: vamzel@epigene.com
TOTAL NO. OF PAGES: 37 Ref. No.: USSN 09/093,972 (EPI-00672)
(including cover page)

CONFIDENTIALITY NOTICE

The information in this fax transmission and the documents accompanying it contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individuals or entities named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this faxed information is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone to arrange for return of the original documents to us.

COMMENTS

Enclosed is a Supplemental Amendment of March 28, 2001, and a clean set of claims.

Please fax a Notice of Allowance today. Thanks.

SERIAL NO: 08/093,972

PATENT


#31/F
Pop
4-26-01
(NE)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jonathan W. Nyce : Art Unit: 1635
Serial No.: 09/093,972 : Examiner: Dr. Epps
Filed: June 9, 1998 : Appl. Ref. No.: EPI-00672
For: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION &
TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICITION, ALLERGY(IES) & INFLAMMATION

SUPPLEMENTAL AMENDMENT

I hereby certify that this correspondence is being faxed at 703-305-7939, to the Assistant Commissioner for Patents, Washington DC 20231 on March 28, 2001, by Viviana Amzel


SIGNATURE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir/Madam:

Supplemental to the response to the Office Action of November 7, 2000, filed February 6, 2001, please amend the above identified patent application as follows.

THE SEQUENCE LISTING

Please ignore the Sequence Listing section filed May 4, 2000, and substitute therefore the one filed March 22, 2001.

Do not delete

IN THE CLAIMS

Please delete claims 175, 176 and 190, and amend the remaining claims as follows.

108. (Amended) A pharmaceutical composition, comprising a carrier; a nucleic acid in the form of an aerosol or spray that comprises one or more oligonucleotide(s) (oligo(s)) effective to alleviate hyper-responsiveness to, and/or increased levels of, adenosine, bronchoconstriction, allergy(ies) and/or inflammation, and contains up to and including about 15% adenosine (A), the oligo being anti-sense to an initiation codon, a coding region or a 5' or 3' intron-exon junctions of a gene encoding an adenosine A1, A2a, A2b or A3 receptor or anti-sense to their respective mRNA;

OKAY
TP
11/07/01
SUB M1
FL